BrainStorm Cell Therapeutics appoints former FDA official Peter Pitts to board

Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc.

BCLI

0.00
  • BrainStorm Cell Therapeutics appointed former FDA Associate Commissioner Peter J. Pitts to its board, effective immediately.
  • Pitts is president and co-founder of the Center for Medicine in the Public Interest.
  • The appointment comes as the company prepares to launch its Phase 3b ENDURANCE trial of NurOwn for ALS, subject to funding.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605280745PR_NEWS_USPR_____LN70150) on May 28, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.